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Triple stimulation techniqueh i g h l i g h t s
 - Triple stimulation technique can be used in routine clinical practice and in multicenter studies in
ALS patients.
 - Assessment of corticospinal dysfunction at the first visit of the patient was improved by the use of
triple stimulation technique compared to conventional TMS.
 - Triple stimulation technique results are correlated with the clinical upper motor neuron score and
ALSFRS-R.
a b s t r a c t
Objective: To evaluate the relevance of transcranial magnetic stimulation (TMS) using triple stimulation
technique (TST) to assess corticospinal function in amyotrophic lateral sclerosis (ALS) in a large-scale
multicenter study.
Methods: Six ALS centers performed TST and conventional TMS in upper limbs in 98 ALS patients during
their first visit to the center. Clinical evaluation of patients included the revised ALS Functional Rating
Scale (ALSFRS-R) and upper motor neuron (UMN) score.
Results: TST amplitude ratio was decreased in 62% of patients whereas conventional TMS amplitude ratio
was decreased in 25% of patients and central motor conduction time was increased in 16% of patients. TST
amplitude ratio was correlated with ALSFRS-R and UMN score. TST amplitude ratio results were not dif-
ferent between the centers.
Conclusions: TST is a TMS technique applicable in daily clinical practice in ALS centers for the detection of
UMN dysfunction, more sensitive than conventional TMS and related to the clinical condition of the patients.
Significance: This multicenter study shows that TST can be a routine clinical tool to evaluate UMN dysfunc-
tion at the diagnostic assessment of ALS patients.
 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights
reserved.
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Among the major requirements to develop effective neuropro-
tective treatment for amyotrophic lateral sclerosis (ALS), the early
therapeutic intervention is pivotal. This requires very sensitive
diagnostic criteria. The diagnosis of ALS is based upon association
of upper (UMN) and lower (LMN) motor neuron alteration. How-
ever, clinical UMN signs are sometimes difficult to assess in ALS
patients, due either to the combination with LMN signs which
may mask them or to their absence especially in the early stages
of the disease. The development of objective UMN biomarkers is
therefore necessary. Unlike electromyography (EMG) which has
the same diagnostic significance as clinical LMN signs (de
Carvalho et al., 2008), UMN signs are defined only by clinical exam-
ination in the revised El-Escorial diagnostic criteria (Brooks et al.,
2000) as well as in the recent Gold Coast criteria (Shefner et al.,
2020). Transcranial magnetic stimulation (TMS) techniques,
though, have long shown their usefulness in assessing UMN dys-
function in ALS (de Carvalho et al., 2008; Huynh et al., 2018;
Pouget et al., 2000; Ziemann and Eisen, 2004). However, to date,
none of these techniques has shown enough diagnostic accuracy
to be widely used in the diagnostic strategy of ALS patients. The
results of TMS studies in ALS remain indeed variable, depending
on the TMS technique and methodology used, the clinical hetero-
geneity and the disease stage of the patients. Hence, it is necessary
to have a TMS technique applicable in clinical practice, evaluated
in a large number of patients and by different teams and sensitive
at the early stages of the disease.
Triple stimulation technique (TST) is a TMS technique devel-
oped by Magistris et al. providing a quantitative electrophysiolog-
ical measure of the central motor conduction failure (Magistris
et al., 1998). The desynchronization of the descending action
potentials evoked by conventional TMS causes a variability in the
size of the motor evoked potentials (MEPs) which therefore does
not allow precise detection and quantification of corticospinal con-
duction failure. In healthy subjects as well as in patients, ampli-
tudes of MEPs are indeed usually much smaller than those of
motor responses to maximal peripheral nerve stimulation and
show variation between normal subjects and from one stimulus
to another. TST uses a collision technique to reduce the degree of
desynchronization of MEPs and thus allows a more precise and
reproducible quantification of the proportion of functional motor
neurons emitting the descending corticomotoneuronal volley after
activation by TMS. TST has been shown to be both sensitive and
specific for the detection of UMN dysfunction in ALS patients
(Attarian et al., 2007; Furtula et al., 2013; Grapperon et al., 2014;
Kleine et al., 2010; Komissarow et al., 2004; Magistris et al.,
1999; Rösler et al., 2000; Wang et al., 2019). However, TST is not
yet widely used and requires validation with a large sample of
patients at the diagnostic assessment through a multicenter
prospective study.2. Methods
2.1. Study participants
ALS patients were prospectively recruited in six ALS centers:
Paris, Lyon, Lille, Clermont-Ferrand and Marseille, France and
Liege, Belgium. The protocol was approved by the ethics commit-
tees. Written informed consent was obtained from all patients.
Paris, Lille, Lyon, Marseille and Clermont-Ferrand centers included
ALS patients in the French PULSE study (Study of Predictive Factors
of Progression of Motor Neuron Disease, Protocol ID: 2013-
A00969-36; ClinicalTrials.gov: NCT02360891) coordinated by the
University Hospital of Lille in partnership with the Association2552for the Research in Amyotrophic Lateral Sclerosis (ARSLA). In PULSE
study, TST is part of the optional ancillary tests performed at the
first patient visit for diagnostic assessment.
The diagnosis of the patients was made by the physicians of the
ALS centers (V.D., E.B., L.J., F.W., S.D., A.M., F.S., P.F.P., T.L., N.G., A.M.
G., E.D., A.V. and S.A.). Patients had to fulfil the revised El Escorial
criteria for possible, probable-laboratory supported, probable or
definite ALS (Brooks et al., 2000). Progressive muscular atrophy
(PMA) patients were also included. PMA is the ALS subtype
restricted to LMN (Ludolph et al., 2015) which was not included
in the revised El Escorial criteria but in the recent Gold Coast crite-
ria (Shefner et al., 2020). The diagnosis of PMA was made based on
the presence of pure LMN clinical and EMG findings after ruling out
other LMN diseases by extensive examinations, neuroimaging, bio-
logical and genetic tests. A standard electrodiagnostic evaluation
was performed for all patients according to the Awaji criteria (de
Carvalho et al., 2008) including full nerve conduction study testing
of at least 8 motor and 6 sensory nerves and needle EMG of at least
4 muscles in lower limbs, 4 muscles in upper limbs, 2 muscles in
thoracic region and 2 muscles in bulbar region. Patients were not
included if they had other neurological conditions that could influ-
ence the results (e.g. stroke, cervical spondylotic myelopathy). All
patients were followed up in the ALS centers allowing diagnosis
confirmation.
2.2. Clinical evaluation
The clinical evaluation of the patients was performed on the day
of the electrophysiological protocol and included disease duration,
onset site, revised ALS functional rating scale (ALSFRS-R)
(Cedarbaum et al., 1999), disease progression rate (i.e. [48-
ALSFRS-R]/disease duration in months) and an UMN score
(Turner et al., 2004). The UMN score consisted of the number of
pathologically brisk reflexes (biceps, triceps, supinator, knee, ankle,
jaw jerk reflex, Hoffmann and Babinski signs), the maximal abnor-
mal value was 15.
2.3. Electrophysiological protocol
TMS techniques were performed by trained neurophysiologists
(A.D., L.J., N.G., R.M.K., F.W., A.M.G. and S.A.). Annual meetings were
organized for the participants to ensure the proper implementa-
tion of the protocol, share their practical experience and ensure
the harmonization of the practice. TMS was performed by using a
Magstim 200 stimulator (Magstim, Whitland, Wales) with a circu-
lar coil (9-cm diameter). Surface EMG signals were recorded with a
bandpass filter of 3–10 000 Hz using an EMG machine which was
also used to perform electrical stimulation. Two types of EMG
machine were used: Nicolet Viking EDX (Natus Medical Incorpo-
rated) in the centers of Marseille, Lyon, Lille and Clermont-Ferrand
or Dantec Keypoint G4 EMG Workstation (Natus Medical Incor-
porated) in the centers of Paris and Liege. Compoundmuscle action
potentials (CMAPs) of the right and left abductor digiti minimi
(ADM) muscles were recorded with disposable disc electrodes in
a tendon-belly configuration. TMS intensity was set at 130% of
the resting motor threshold. TST was performed as described in
previous studies (Attarian et al., 2015, 2007, 2005; Corazza et al.,
2020; Deroide et al., 2007; Eusebio et al., 2007; Grapperon et al.,
2019, 2014; Rico et al., 2009; Sevy et al., 2018) in accord with
the practical guidelines for diagnostic TMS of the International
Federation of Clinical Neurophysiology (Groppa et al., 2012). This
technique consists first of the delivery of a magnetic stimulation
on the motor cortex, followed by a supra-maximal electrical stim-
ulation at the wrist on the ulnar nerve, so that the descending cor-
ticomotoneuronal volley collides with the antidromic action
potentials. The collision takes place in the proximal portion of
Table 1
Clinical characteristics of the 98 patients (mean value ± SD).
Age (100%) 59 ± 13 yrs
Sex M/F (100%) 62 / 36 (63% / 37%)
Disease duration (97%) 17 ± 14 months
Onset site (97%) Spinal: 77% (upper limb 40%, lower limb 37%)
Bulbar: 22%
Respiratory: 1%
Diagnostic criteria (97%) Definite ALS: 16%
Probable ALS: 38%
Probable-laboratory supported ALS: 19%
Possible ALS: 15%
PMA: 12%
ALSFRS-R (/48) (100%) 40 ± 6
Disease progression rate (/month) (99%) 0.8 ± 0.8
UMN score (/15) (54%) 6 ± 4
The percentages of available data are noted in brackets in the first column. Abbreviations: ALS, amyotrophic lateral sclerosis;
ALSFRS-R, revised ALS functional rating scale; PMA, progressive muscular atrophy; UMN, upper motor neuron
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delivered at the Erb point, allowing the acquisition of a highly syn-
chronized response from the fibers in which the collision occurred.
This response is compared to the response obtained after the con-
trol triple stimulation Erb point - wrist - Erb point to calculate TST
amplitude ratio. TST amplitude ratio therefore reflects the number
of functional neurons emitting the descending corticomotoneu-
ronal volley.
Each center collected the following data for the left and right
ADM muscles: 1) CMAP amplitudes elicited by peripheral electric
stimulation of ulnar nerve at the wrist, 2) conventional TMS ampli-
tude ratio (conventional TMS amplitude ratio = TMS MEP ampli-
tude / CMAP amplitude), 3) central motor conduction time
(CMCT = MEP latency – [minimal F-wave latency + CMAP latency
– 1] /2), 4) TST amplitude ratio. TMS and TST were not performed
if CMAP amplitude was < 1 mV.
Normal values of TST were developed in previous studies
(Attarian et al., 2007; Magistris et al., 1999, 1998; Rösler et al.,
2000). Control values were also obtained from 38 healthy subjects:
mean value was 96.8% +/- 3.87, normal value using 2.5 SD limits
was 87%. No healthy subject had a TST amplitude ratio < 90%,
which is why this threshold of normal value was chosen. Labora-
tory standards established in the centers for the other parameters
are as follows: abnormal conventional TMS amplitude ratio if < 33%
and abnormal CMCT if > 10 ms.
2.4. Statistical analyses
Statistical analyses were performed by using SAS software (ver-
sion 9.4, SAS Institute, Cary, NC) and GraphPad Prism 5 (California,
USA).
Given the heterogeneity and size of the sample, a Spearman
rank test was used to evaluate associations between TST amplitude
ratio and conventional TMS amplitude ratio as well as associations
between TMS parameters (mean value between the right and left
ADM TST amplitude ratio, conventional TMS amplitude ratio and
CMCT) and clinical data (ALSFRS-R and UMN score). The difference
between the proportion of abnormal TST amplitude ratio and
abnormal conventional TMS amplitude ratio on at least one side
was analyzed by using the Fisher exact test.
The Kruskal-Wallis test and the Mann–Whitney–Wilcoxon test
were used to determine differences in TMS parameters (TST ampli-
tude ratio, conventional TMS amplitude ratio and CMCT) between
the centers. The difference of the percentage of patients with
abnormal TST amplitude ratio, conventional TMS amplitude ratio
and CMCT on at least one side between the centers was analyzed
by using the Fisher exact test. We also verified that the patients
of the centers were similar with regard to the distribution of clin-2553ical data by using the Fisher exact test for sex and onset site, the
Kruskal-Wallis test for age, disease duration, disease progression
rate, ALSFRS-R and UMN score. The Mann-Whitney test was used
for pairwise comparisons with Tukey adjustment of p-values.3. Results
3.1. Study participants
Ninety-eight patients were included in the study from January
13, 2016 to February 12, 2020. Fifty-two patients were included
in the center of Marseille, 13 patients in the center of Paris, 12
patients in the center of Lyon, 10 patients in the center of Liege,
8 patients in the center of Lille and 3 patients in the center of
Clermont-Ferrand.
Demographic and clinical characteristics of the patients are
reported in Table 1.3.2. Conventional TMS and TST results
Conventional TMS and TST results are given in Table 2.
TST amplitude ratio was abnormal on at least one side in 61/98
(62%) patients while conventional TMS amplitude ratio was abnor-
mal on at least one side in 21/84 (25%) patients. TST amplitude
ratio was significantly more often abnormal than conventional
TMS amplitude ratio (p = 0.001). TST amplitude ratio and conven-
tional TMS amplitude ratio were correlated (rho = 0.68, p < 0.001
for the right ADM and rho = 0.66, p < 0.001 for the left ADM)
(Fig. 1).
TST and TMS results according to the diagnostic criteria of the
patients are represented in Table 3. In the subgroup of PMA and
possible ALS patients, 15/26 (58%) patients had an abnormal TST
amplitude ratio on at least one side while only 2/19 (11%) patients
had an abnormal conventional TMS amplitude ratio on at least one
side (p = 0.002).
The rate of abnormal TST amplitude ratio in patients with clin-
ical evidence of UMN in the limb tested was 88%.3.3. Correlations between TMS and clinical data
TST amplitude ratio was correlated with ALSFRS-R (rho = 0.23,
p = 0.03) and with the UMN score (rho =  0.31, p = 0.04)
(Fig. 2). Conventional TMS amplitude ratio was also correlated with
the UMN score (rho =  0.42, p = 0.01) but not with ALSFRS-R
(rho = 0.08, p = 0.48). CMCT was not correlated with ALSFRS-R
(rho = 0.21, p = 0.11) nor with the UMN score (rho = 0.14, p = 0.27).
Table 2
TMS and TST results (mean value ± SD).
TMS parameters CMAP (mV) TST amplitude ratio (%) Conventional TMS amplitude ratio (%) CMCT (ms)
Abnormal value < 5.0 < 90 < 33 > 10
Right ADM 5.4 ± 2.7 (97%) 75 ± 34 (91%) 52 ± 29 (83%) 8 ± 4 (64%)
Left ADM 5.3 ± 2.7 (97%) 73 ± 36 (87%) 50 ± 30 (82%) 8 ± 4 (63%)
% of patients with an abnormal result on at least one side 57% 62% ** 25% 16%
In brackets are noted the percentages of available data.
Abbreviations: ADM, abductor digiti minimi; CMAP, compound muscular action potential; CMCT, central motor conduction time; TMS, transcranial magnetic stimulation;
TST, triple stimulation technique.
** Comparison between TST amplitude ratio and conventional TMS amplitude ratio (p < 0.01).
Fig. 1. Correlation between TST amplitude ratio and conventional TMS amplitude ratio (median value between right and left ADM). Abbreviations: ADM, abductor digiti
minimi; TMS, transcranial magnetic stimulation; TST, triple stimulation technique.
Table 3
TST and TMS results according to the diagnostic criteria of the patients.
Diagnostic
criteria
Number of patients with an
abnormal TST amplitude
ratio on at least one side /
total of patients
Number of patients with an
abnormal conventional TMS
amplitude ratio on at least
one side / total of patients
Definite ALS
(n = 15)
11 / 15 (73.3%) 3 / 13 (23.1%)
Probable ALS
(n = 36)




ALS (n = 18)
11 / 18 (61.1%) 3 / 18 (16.7%)
Possible ALS
(n = 14)
9 / 14 (64.3%) 1 / 8 (12.5%)
PMA (n = 12) 6 / 12 (50%) 1 / 9 (11.1%)
Abbreviations: ALS, amyotrophic lateral sclerosis; PMA, progressive muscular
atrophy; TMS, transcranial magnetic stimulation; TST, triple stimulation technique.
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The TST results of the six centers are given in Table 4 and are
represented in Fig. 3. Clermont-Ferrand center’s data was not used
for the comparative analysis between the centers due to the small
number of patients included. TST amplitude ratio was not signifi-
cantly different between the centers (p = 0.65 for the right ADM,
p = 0.19 for the left ADM). The other TMS parameters were not sig-
nificantly different either (p > 0.05) except for the conventional
TMS amplitude ratio of the left ADM (Kruskal-Wallis test2554p = 0.04, no significant pairwise comparison; p < 0.05 adjusted
Tukey).
Regarding the clinical data of the patients, ALSFRS-R was signif-
icantly different between the centers (Kruskal-Wallis test,
p = 0.03), ALSFRS-R was lower in Paris than in Lyon (Mann-
Whitney test, p = 0.01) and was not significantly different between
the other centers (Mann-Whitney test, p > 0.05). UMN score was
significantly different between the centers (Kruskal-Wallis test,
p = 0.01), UMN score was lower in Lyon than in Marseille (Mann-
Whitney test, p = 0.01) and was not significantly different between
the other centers (Mann-Whitney test, p > 0.05). The other clinical
data including age, sex, onset site, disease duration and disease
progression rate were not significantly different between the cen-
ters (p > 0.05).
The percentage of patients with an abnormal TST amplitude
ratio, conventional TMS amplitude ratio or CMCT on at least one
side was not significantly different between the centers (p > 0.05).4. Discussion
This multicenter study shows that TST can be performed by dif-
ferent centers in a large number of ALS patients and improves sig-
nificantly the results obtained with conventional TMS techniques.
TMS abnormalities commonly found in ALS, prolonged CMCT
and small or unobtainable MEPs, lack sensitivity and the results
of the different studies are somewhat inconsistent (Chen et al.,
2008). The variability in the results can be explained by the differ-
ence between TMS techniques and methods used and by the differ-
Fig. 2. Correlation between TST amplitude ratio and clinical data (ALSFRS-R and UMN score). Abbreviations: ALSFRS-R, revised amyotrophic lateral sclerosis functional rating
scale; TST, triple stimulation technique; UMN, upper motor neuron.
Table 4
. TST results in the six centers (mean ± SD).
Center TST amplitude ratio right
ADM (%)
TST amplitude ratio left
ADM (%)
Paris (n = 13) 73 ± 34 66 ± 38
Marseille (n = 52) 68 ± 38 63 ± 37
Lyon (n = 12) 87 ± 24 83 ± 26
Liège (n = 10) 85 ± 19 86 ± 18
Lille (n = 8) 80 ± 18 79 ± 18
Clermont-Ferrand
(n = 3)
92 ± 14 100 ± 0
Abbreviations: ADM, abductor digiti minimi; TST, triple stimulation technique.
Fig. 3. TST amplitude ratio distribution in the 6 centers. Abbreviation: TST, triple
stimulation technique.
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studies are often based on a small sample size of ALS patients while
TMS results are influenced by the stage of the disease and the clin-
ical presentation of the patients (UMN vs LMN-predominant or
bulbar vs spinal forms for example). This study included a large
number of patients who were examined at the time of their diag-
nostic assessment, which allowed to evaluate in real life the diag-
nostic interest of TST.
TST has been shown to be at least two times more sensitive than
conventional TMS to detect corticospinal conduction deficit in ALS
(Attarian et al., 2007; Bühler et al., 2001; Kleine et al., 2010;2555Komissarow et al., 2004; Rösler et al., 2000), which has been con-
firmed by this study showing an abnormal amplitude ratio with
TST in 62% of ALS patients against 25% with conventional TMS.
Decreased conventional TMS amplitude ratio can be explained by
the corticospinal conduction failure occurring in ALS due to UMN
dysfunction. However, it is not a sensitive marker because MEP
size is a variable parameter even in healthy subjects and, in ALS,
the desynchronization of the descending volleys after TMS is often
abnormally increased (Attarian et al., 2008, 2006; Awiszus and
Feistner, 1993; Mills, 1995). TST synchronizes the response of the
motor neurons driven to discharge by TMS, thereby avoiding phase
cancellation that accompanies the desynchronization of the bipha-
sic motor unit potentials and eliminates repetitive discharges from
the measured response. Unlike conventional TMS amplitude ratio
measurement, TST therefore allows a precise quantification esti-
mation of corticospinal conduction failure caused by UMN dys-
function which probably occurs early in the disease. Another
conventional TMS parameter that is often abnormal in ALS is
CMCT. CMCT measurement allows an estimate of the conduction
time of corticospinal fibers between motor cortex and LMN. CMCT
prolongation in ALS can be explained by the degeneration of the
fastest conducting corticospinal fibers. CMCT measurement has
also been shown useful to detect UMN dysfunction in ALS patients
without clinically predominant UMN signs but may have low sen-
sitivity in the early stages of the disease (Eisen et al., 1996; Floyd
et al., 2009; Huynh et al., 2018; Kohara et al., 1996; Mills, 2003;
Tokimura et al., 2020), which is confirmed by this study showing
that CMCT is rarely abnormal at the time of the patient’s initial
diagnostic visit.
This study confirms that TST is an easy-to-perform and widely
usable technique in clinical practice. The TST exam lasts about 20
minutes and is well tolerated by the majority of patients, although
electrical stimulation at Erb’s point is very often considered
uncomfortable as in nerve conduction study. Good TST practice is
easy to learn and perform well for neurophysiologists experienced
in practicing TMS. A half-day training session is usually sufficient
to learn TST practice for confirmed neurophysiologists.
This study focused on TST, one of the most accurate neurophys-
iological measure to detect corticospinal conduction deficits, but
TST does not allow the study of cortical inhibition and facilitation.
Other TMS techniques involving paired-pulse have studied cortical
excitability in ALS (Vucic et al., 2013). Threshold-tracking TMS
studies have thus shown that an absent or reduced short-interval
intracortical inhibition is an early marker in ALS with high sensitiv-
ity and specificity (Menon et al., 2015; Vucic et al., 2018, 2011).
However, these TMS techniques are not yet widely used in clinical
practice.
Aude-Marie Grapperon, A. Verschueren, E. Jouve et al. Clinical Neurophysiology 132 (2021) 2551–2557This multicenter study shows that TST can be used by different
centers in clinical practice and has allowed this technique to be
studied in a large number of patients. A limitation of this study
is that the number of patients included in several institutions
was small. Thus, the results of the analyses of institutional differ-
ences should be interpreted with caution and need to be confirmed
in larger multicenter studies. However, despite this limitation, con-
sistent results were observed between the different centers.
Another limitation of the study is the absence of a control group.
Normal values have been developed in previous studies (Attarian
et al., 2007; Magistris et al., 1999, 1998; Rösler et al., 2000). The
limit of normal TST value of 90% was established because in previ-
ous studies no healthy control had a TST amplitude ratio < 90%. In
addition, each of the centers had been trained by Michel Magistris
and the harmonization of the technique was verified for this study
by training sessions. Lastly, another limitation of the study is that
TST was only performed in the upper limbs. Adding TST in the
lower limbs could further improve sensitivity but is a more inva-
sive technique. TST and TMS techniques are also limited in cases
of important limb atrophy (CMAP < 1 mV).
Interestingly, TST amplitude ratio correlated with the clinical
scores including the ALSFRS-R that is the gold standard measure of
clinical incapacity in ALS and the UMN score. It is indeed important
that an electrophysiological marker used in daily practice be corre-
lated with the clinical incapacity of patients. These correlations were
however low (ALSFRS-R, rho = 0.23; UMN score, rho = -0.31). This
may be explained by the fact that these clinical scores depend on
both LMN and UMN involvement whereas TST explores UMN dys-
function. The presence of a significant correlation between UMN
score and TST abnormalities shows that the corticospinal dysfunction
measured by TST could have a clinical implication. UMN score is an
easy-to-use score allowing rapid clinical assessment of UMN signs.
This score was only available for 53/98 patients because it was
included in the optional clinical data set.
In this study, half of the PMA patients had an abnormal TST
amplitude ratio. The perspective is therefore to study a larger num-
ber of PMA patients since TMS techniques have the greatest diag-
nostic utility for these patients. These results are in line with
post mortem studies capturing subclinical corticospinal tract
degeneration in half of the cases with PMA (Ince et al., 2003).
TST which allows detecting subclinical UMN involvement can thus
be useful in improving the diagnosis of PMA which is often chal-
lenging. TST is also useful for patients in whom UMN signs are
unclear, for example limited to brisk reflexes, since clinical UMN
signs may be masked by LMN signs, or which appear later in the
course of the disease. The sensitivity of ALS diagnostic criteria
could be improved by the addition of TMS techniques and a dedi-
cated study would be interesting to evaluate it. However, the main
question of whether atypical ALS phenotypes such as PMA should
be included in therapeutic trials remains unresolved as their
response to treatments may be different from classical ALS.
In conclusion, this multicenter study shows that TST can be
used in routine clinical practice in ALS patients and improves the
assessment of corticospinal dysfunction compared to conventional
TMS at the first evaluation of the patients.
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